Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Chronic Kidney Disease, Hypertension, Diabetes
Interventions: Exercise training; Behavioral
Lead sponsor: Springfield College; Other
Eligibility: 35 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Retinal Disease, Glaucoma, Optic Nerve Diseases
Interventions: Investigational contact OCT system, Investigational noncontact OCT system:; Device
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Interventions: treprostinil SMI (treprostinil inhalation spray), Placebo (placebo inhalation spray); Combination Product
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 12 more

Conditions: Hypertension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure
Interventions: Heating pad, Sham control; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Hypertension
Interventions: Diagnostic imaging procedures.; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension, Dyslipidemia, Hyperglycemia
Interventions: Xocai Activ drink; Dietary Supplement
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 95 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: MDbackline, LLC; Other
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Hypertension
Interventions: Furosemide, Potassium chloride, Placebo #1, Placebo #2; Drug
Lead sponsor: Indiana University; Other
Eligibility: Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Indianapolis, Indiana • St Louis, Missouri

Conditions: Cardiovascular Disease (CVD), Hypertension, Hyperlipemia, Obesity
Interventions: Community-based peer health coach intervention; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Up to 75 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Essential Hypertension
Interventions: Magnesium citrate, tribasic anhydrous soft gelatin capsule, Placebo soft gelatin capsule; Drug
Lead sponsor: RMJ Holdings, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Tustin, California

Conditions: Hypertension
Interventions: Health Coaching, Home Blood Pressure Monitoring; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Stress, Hypertension
Interventions: VR Stress Management, Education Control; Other · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 21 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypertensive Disorder of Pregnancy, Pre-Eclampsia, Hypertension, Eclampsia, Gestational Hypertension, Cardiovascular Diseases, Toxemia, Pregnancy Complications, Vascular Diseases, Hypertension, Pregnancy Induced, Hypertension;Pre-Eclamptic
Interventions: Usual care, Tight blood pressure control; Drug
Lead sponsor: Alisse Hauspurg; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Open-angle Glaucoma
Interventions: Pilocarpine Concentration, Pilocarpine Frequency; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 90 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1978 – 1979
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions: Ralinepag; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 48
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more

Conditions: Essential Hypertension
Interventions: Lisinopril, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 9 Years to 22 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension
Interventions: Azilsartan Medoxomil and amlodipine, Amlodipine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 50
States / cities: Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 47 more

Conditions: Gestational Diabetes, Gestational Hypertension, High Risk Pregnancy, Preeclampsia
Interventions: Maternal Health Management Program; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Portal Hypertension, Chronic Liver Disease
Interventions: ARFI ultrasound; Device
Lead sponsor: VA Connecticut Healthcare System; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: New Haven, Connecticut • West Haven, Connecticut

Conditions: Heart Failure, Coronary Artery Disease, Peripheral Artery Disease, Ischemia, Hypertension, Diabetes Mellitus, Cardiomyopathies, Cardiotoxicity
Interventions: Clinical Decision Aid, Standard Care; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pulmonary Arterial Hypertension
Interventions: macitentan (ACT-064992), placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 33
States / cities: Birmingham, Alabama • Pheonix, Arizona • Los Angeles, California + 28 more

Conditions: Pre-Eclampsia
Interventions: L-arginine supplementation in a medical food, Vitamin C and E supplementation in a medical food; Procedure
Lead sponsor: Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes; Government
Eligibility: 19 Years to 32 Years · Female only
Enrollment: 585 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: CTC Intervention, Control; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Chicago, Illinois • Bedford, Massachusetts • Philadelphia, Pennsylvania

Conditions: Preeclampsia, Pregnancy
Interventions: Mitoquinol Mesylate, Placebo; Dietary Supplement · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Aerobic Training and Arterial Stiffness in Chronic Kidney Disease (CKD) Patients

Optimize Pediatric OCT Imaging

Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension

Right Ventricular Hypertrophy and Pulmonary Hypertension: A Correlation Analysis

Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors

Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops

Prevention of Severe Postpartum Hypertension

Veteran Peer Coaches Optimizing and Advancing Cardiac Health

Safety Study of RMJH-111b to Treat Essential Hypertension

Staying Healthy After Childbirth: My Hypertension Education and Reaching Target Program for Postpartum

Virtual Reality Intervention for Stress, Resilience, and Blood Pressure Management in Black Women - Realist Women Study

Optimal Blood Pressure Treatment Thresholds Postpartum

Dose, Effects and Characteristics of Pilocarpine

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

Preventing Obstetric Complications With Dietary Intervention

Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI)

PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

L-Arginine and Antioxidant Vitamins During Pregnancy to Reduce Preeclampsia

Continuing the Conversation: Using Narrative Communication to Support Hypertension Self-management in African American Veterans

MitoQ to Improve Vascular Funciton in Preeclampsia